Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Introduction: Dementia is a group of disorders that causes dysfunctions in human cognitive and operating functions. Currently, it is not possible to conduct a fast, low-invasive dementia diagnostic process with the use of peripheral blood biomarkers, however, there is a great deal of research in progress covering this subject. Research on dementia biomarkers in serum validates anticipated health and economic benefits from early screening tests. Biomarkers are also essential for improving the process of developing new drugs. Methods: The result analysis, of current studies on selected biomarker concentrations (Aβ40, Aβ42, t-tau, and YKL-40) and their combination in the serum of patients with dementia and mild cognitive disorders, involved a search for papers available in Medline, PubMed, and Web of Science databases published from 2000 to 2020. Results: The results of conducted cross-sectional studies comparing Aβ40, Aβ42, and Aβ42/Aβ40 among people with cognitive disorders and a control group are incoherent. Most of the analyzed papers showed an increase in t-tau concentration in diagnosed Alzheimer’s disease (AD) patients’ serum, whereas results of mild cognitive impairment (MCI) groups did not differ from the control groups. In several papers on the concentration of YKL-40 and t-tau/Aβ42 ratio, the results were promising. To date, several studies have only covered the field of biomarker concentrations in dementia disorders other than AD. Conclusions: Insufficient amyloid marker test repeatability may result either from imperfection of the used laboratorial techniques or inadequate selection of control groups with their comorbidities. On the basis of current knowledge, t-tau, t-tau/Aβ42, and YKL-40 seem to be promising candidates as biomarkers of cognitive disorders in serum. YKL-40 seems to be a more useful biomarker in early MCI diagnostics, whereas t-tau can be used as a marker of progress of prodromal states in mild AD. Due to the insignificant number of studies conducted to date among patients with dementia disorders other than AD, it is not possible to make a sound assessment of their usefulness in dementia differential diagnostics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992 · cited 4×
“Neurodegenerative dementia includes the following: dementia in Alzheimer’s disease, dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), dementia in Parkinson’s disease (PDD), Huntington’s disease (HD), and dementia in prion diseases.”
BackgroundInfluential2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Neuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726 · cited 1×
“These cells are activated by proinflammatory cytokines, as well as Aβ and APP, causing the release of neurotoxic proinflammatory cytokines and reactive oxygen forms, and resulting in intensification of the inflammatory process and oxidative stress [41].”
BackgroundO'Brien, J. T., & Thomas, A. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00463-8 · Cited by 1,136
Review Article: Genetics of Alzheimer Disease
Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383571 · Cited by 1,029
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 1×
“…(10.3) MCI 56.8 (9.3) HC 36.3 (6.3) 0.001 (MCI vs. AD + HC) AD 4.6 (0.9) MCI 2.9 (0.6) HC 4.5 (0.6) 0.001 (MCI vs. AD + HC) ELISA Pesaresi et al., 2006 [69] 324 AD (146), MCI (89), HC (89) - - AD 38 MCI 52 HC 54 0.01 (AD vs. MCI + HC) - - ELISA Fagan et al., 2007 [70] 114 AD CDR1 (16), AD CDR0.”
InfluentialAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0079-7 · Cited by 716 · cited 5×
“Adequate biochemical markers could be an inestimable tool in the hands of family physicians, facilitating selection of patients in need of specialist treatment [61].”
BackgroundInfluentialPlasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626
Mielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.013 · Cited by 621 · cited 2×
“, 2018 [39] 267 AD (40), MCI (57), HC (172) AD 7.”
Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease
Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504 · cited 12×
“It is believed that the concentration of tau protein in CSF relates to the degree of brain cells damage [37].”
BackgroundResultInfluentialPlasma tau in Alzheimer disease
Mattsson, N., Zetterberg, H., Janelidze, S., Insel, P. S., Andreasson, U., Stomrud, E., Palmqvist, S., Baker, D., Tan Hehir, C. A., Jeromin, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003246 · Cited by 502
Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200861 · Cited by 437 · cited 1×
“Hyperphosphorylated tau protein and its isoforms, such as p-tau-217, measured in the peripheral blood are also promising AD biomarker candidates [35].”
BackgroundVascular pathologies and cognition in a population-based cohort of elderly people
Fernando, M. S., & Ince, P. G. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.09.004 · Cited by 239 · cited 3×
“It has been proven that the density of congophilic vascular lesions increased with the severity of cognitive impairment [7].”
BackgroundInfluentialQuerol-Vilaseca, M., Colom-Cadena, M., Pegueroles, J., San Martín-Paniello, C., Clarimon, J., Belbin, O., Fortea, J., & Lleó, A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0893-7 · Cited by 158 · cited 2×
“On the one hand, increased YKL-40 immunoreactivity in brain, correlating with tau protein, was observed in tauopathies other than AD [58].”
BackgroundEarly microglial activation and peripheral inflammation in dementia with Lewy bodies
Surendranathan, A., Su, L., Mak, E., Passamonti, L., Hong, Y. T., Arnold, R., Vázquez Rodríguez, P., Bevan-Jones, W. R., Brain, S. A. E., Fryer, T. D., et al. (2018) · Brain · doi:10.1093/brain/awy265 · Cited by 154
Dage, J. L., Wennberg, A. M. V., Airey, D. C., Hagen, C. E., Knopman, D. S., Machulda, M. M., Roberts, R. O., Jack, C. R., Petersen, R. C., & Mielke, M. M. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.001 · Cited by 145
Tau biology, tauopathy, traumatic brain injury, and diagnostic challenges
Castellani, R. J., & Perry, G. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180721 · Cited by 110 · cited 7×
“This protein is found mainly inside neurons (especially in microtubule-rich axons), but also, to a lesser extent, in glial cells (astocytes and oligodendrocytes) [32], as well as in extracellular space [33].”
BackgroundInfluentialCerebral amyloid angiopathy as a cause of neurodegeneration
Smith, E. E. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14157 · Cited by 86 · cited 2×
“Contrary to AD, where amyloid deposits locate mainly (but not exclusively) into intercellular space, in CAA subjects, the lesions are predominately in the blood vessel walls [3].”
BackgroundAlcohol-Related Dementia: A Systemic Review of Epidemiological Studies
Cheng, C., Huang, C.-L., Tsai, C.-J., Chou, P.-H., Lin, C.-C., & Chang, C.-K. (2017) · Psychosomatics · doi:10.1016/j.psym.2017.02.012 · Cited by 64
Plasma tau is increased in frontotemporal dementia
Foiani, M. S., Woollacott, I. O., Heller, C., Bocchetta, M., Heslegrave, A., Dick, K. M., Russell, L. L., Marshall, C. R., Mead, S., Schott, J. M., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317260 · Cited by 64
No correlation between time‐linked plasma and CSF Aβ levels
Le Bastard, N., Aerts, L., Leurs, J., Blomme, W., De Deyn, P. P., & Engelborghs, S. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.08.006 · Cited by 59
Another step forward in blood-based diagnostics for Alzheimer’s disease
Bateman, R. J., Barthélemy, N. R., & Horie, K. (2020) · Nature Medicine · doi:10.1038/s41591-020-0797-4 · Cited by 37
Blood Biomarkers for Alzheimer’s Disease: Much Promise, Cautious Progress
Keshavan, A., Heslegrave, A., Zetterberg, H., & Schott, J. M. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0241-0 · Cited by 34 · cited 5×
“Currently, on the one hand, biomarker identification in cerebrospinal fluid (Aβ42, t-tau, p-tau) requires qualified personnel that can use a more invasive, expensive, and often non-refundable procedure for material extraction [60,63].”
BackgroundInfluentialPlasma biomarkers are associated with agitation and regional brain atrophy in Alzheimer’s disease
Hsu, J.-L., Lee, W.-J., Liao, Y.-C., Lirng, J.-F., Wang, S.-J., & Fuh, J.-L. (2017) · Scientific Reports · doi:10.1038/s41598-017-05390-1 · Cited by 18 · cited 3×
“…23.8 (15.1) MCI 23.6 (12.5) HC 23.7 (12.6) 0.899 (AD vs. MCI) 0.969 (MCI vs. HC) AD 0.15 (0.25) MCI 0.14 (0.07) HC 0.15 (0.08) 0.904 (AD vs. HC) 0.189 (MCI vs. HC) xMAP Hsu et al., 2017 [102] 335 AD (177), MCI (60),HC (108) AD 170.3 (63.9) MCI 171.1 (54.5) HC 143.7 (34.9) 0.0001 (AD vs.…”
ResultInfluential
Cited by
Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses
Needham, E. J., Ren, A. L., Digby, R. J., Norton, E. J., Ebrahimi, S., Outtrim, J. G., Chatfield, D. A., Manktelow, A. E., Leibowitz, M. M., Newcombe, V. F. J., et al. (2022) · Brain · doi:10.1093/brain/awac321 · Cited by 90
“Elevated serum total tau concentrations have been described in patients with tauopathies such as Alzheimer’s disease and frontotemporal dementia, 32 and are associated with trajectory of cognitive decline in these conditions.”
Zhang, B., Chen, T., Cao, M., Yuan, C., Reiter, R. J., Zhao, Z., Zhao, Y., Chen, L., Fan, W., Wang, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.900132 · Cited by 80
Blood Biomarkers for the Diagnosis of Neurodegenerative Dementia: A Systematic Review
Santos, F., Cabreira, V., Rocha, S., & Massano, J. (2023) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887221141651 · Cited by 24
Metadata
- Authors
- Wilczyńska, K., & Waszkiewicz, N.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2020-10-27
- Volume
- 9
- Issue
- 11
- Pages
- 3452
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W3096150216
- Cited by
- 43
- References
- 28
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.